It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Patient Disclaimer / 患者免责声明 / Penafian Pesakit


I hereby acknowledge that I have been recently prescribed Kisqali as part of my medical treatment regimen.

我特此承认,我最近服用了 Kisqali 作为我的治疗方案的一部分。

Saya dengan ini mengakui bahawa saya baru-baru ini telah diberi Kisqali sebagai sebahagian daripada rejimen rawatan perubatan saya.



1. Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023 Aug 31;25(1):103.
2. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950.
3. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients withHR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851-859.